BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Position Reduced by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC reduced its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 5.9% during the 4th quarter, HoldingsChannel.com reports. The fund owned 55,125 shares of the biotechnology company’s stock after selling 3,479 shares during the quarter. Janney Montgomery Scott LLC’s holdings in BioCryst Pharmaceuticals were worth $415,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Geode Capital Management LLC grew its stake in BioCryst Pharmaceuticals by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company’s stock valued at $36,776,000 after acquiring an additional 127,708 shares in the last quarter. Fisher Asset Management LLC boosted its position in shares of BioCryst Pharmaceuticals by 16.9% in the third quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock valued at $25,369,000 after acquiring an additional 481,359 shares during the period. Two Sigma Advisers LP grew its position in BioCryst Pharmaceuticals by 13.6% in the 3rd quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company’s stock worth $16,576,000 after purchasing an additional 261,500 shares during the last quarter. Rice Hall James & Associates LLC raised its holdings in BioCryst Pharmaceuticals by 4.0% in the 3rd quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company’s stock valued at $16,444,000 after acquiring an additional 84,102 shares in the last quarter. Finally, FMR LLC lifted its position in BioCryst Pharmaceuticals by 2.4% in the third quarter. FMR LLC now owns 1,988,389 shares of the biotechnology company’s stock worth $15,112,000 after purchasing an additional 46,110 shares during the period. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

BCRX stock opened at $8.63 on Tuesday. BioCryst Pharmaceuticals, Inc. has a one year low of $4.03 and a one year high of $9.00. The stock has a market cap of $1.79 billion, a price-to-earnings ratio of -14.15 and a beta of 1.75. The company has a fifty day moving average price of $7.75 and a two-hundred day moving average price of $7.73.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on BCRX shares. JMP Securities reissued a “market outperform” rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Evercore ISI raised their target price on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Royal Bank of Canada restated an “outperform” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Needham & Company LLC increased their price target on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, January 13th. Finally, Barclays boosted their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $15.50.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.